Literature DB >> 10720019

Severe hypertension induced by the long-acting somatostatin analogue sandostatin LAR in a patient with diabetic autonomic neuropathy.

R Pop-Busui1, W Chey, M J Stevens.   

Abstract

A 26-yr-old woman with type 1 diabetes and severe symptomatic autonomic neuropathy was treated with the long-acting somatostatin analogue Sandostatin LAR for intractable diarrhea. Her diarrhea had previously been successfully managed with three daily injections of octreotide without adverse consequences. She was given a single dose of Sandostatin LAR and within 2 weeks reported the development of increasingly frequent and severe headaches. Three weeks after the injection, she was admitted to hospital with severe hypertension, which eventually resolved with the administration of antihypertensive agents. No other underlying cause of the hypertension was discovered. Rechallenge of the patient with octreotide resulted in a transient hypertensive episode, which lasted 3 h. Severe hypertension, therefore, seems to be a possible adverse effect of treatment of diabetic diarrhea with somatostatin analogues, which should be used with great caution in subjects with severe autonomic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720019     DOI: 10.1210/jcem.85.3.6401

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

Review 1.  Dysautonomia: perioperative implications.

Authors:  Hossam I Mustafa; Joshua P Fessel; John Barwise; John R Shannon; Satish R Raj; André Diedrich; Italo Biaggioni; David Robertson
Journal:  Anesthesiology       Date:  2012-01       Impact factor: 7.892

2.  Treatment of autonomic neuropathy, postural tachycardia and orthostatic syncope with octreotide LAR.

Authors:  Robert D Hoeldtke; Kimberly D Bryner; Martin E Hoeldtke; Gerald Hobbs
Journal:  Clin Auton Res       Date:  2007-08-31       Impact factor: 4.435

Review 3.  Cardiac autonomic neuropathy in diabetes: a clinical perspective.

Authors:  Rodica Pop-Busui
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.